Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449597 | 0.77 | KDM4E (0.33) | TRPA1 | |
| SCHEMBL4450134 | 0.71 | KDM4E (0.30) | — | |
| SCHEMBL4450135 | 0.71 | KDM4E (0.30) | — | |
| SCHEMBL31707310 | 0.68 | TRPA1 (0.41) | TRPA1 | |
| SCHEMBL444400 | 0.62 | TRPA1 (0.34) | TRPA1 | |
| SCHEMBL239587 | 0.62 | TRPA1 (0.34) | TRPA1 | |
| SCHEMBL23400 | 0.62 | KDM4E (0.35) | TRPA1 | |
| SCHEMBL24623304 | 0.60 | TRPA1 (0.33) | TRPA1 | |
| SCHEMBL9750268 | 0.60 | ALOX5 (0.39) | — | |
| SCHEMBL7098395 | 0.60 | MAPT (0.38) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3245198-B1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | NOVARTIS AG (CH) | 2020-03-11 | — | — | EP | claimed |
| US-10065943-B2 | Pyrrolidine derivatives as angiotensin II type 2 antagonists | NOVARTIS AG (CH) | 2018-09-04 | — | — | US | claimed |
| US-20170369473-A1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2017-12-28 | — | — | US | claimed |
| EP-3245198-A1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | Novartis AG (CH) | 2017-11-22 | — | — | EP | claimed |
| WO-2016113668-A1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | NOVARTIS AG (CH) | 2016-07-21 | — | — | WO | claimed |
| US-20040142979-A1 | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-07-22 | — | — | US | claimed |
| US-5641783-A | ANTIINFLAMMATORY OR IMMUNOSUPPRESSIVE AGENTS | CELL THERAPEUTICS, INC. (US) | 1997-06-24 | — | — | US | claimed |
| US-10786521-B2 | Methods and compositions for treatment of COPD diseases | Shanghai KE Pharmaceutical Co., Ltd (CN) | 2020-09-29 | — | — | US | disclosed |
| EP-3245198-B1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | NOVARTIS AG (CH) | 2020-03-11 | — | — | EP | disclosed |
| EP-3131556-B1 | KUDINOSIDES FOR USE IN THE TREATMENT OF COPD DISEASES | SHANGHAI KE PHARMACEUTICAL CO LTD (CN) | 2019-10-09 | — | — | EP | disclosed |
| US-10308628-B2 | Heterocyclic compounds and methods for their use | NOVARTIS AG (CH) | 2019-06-04 | — | — | US | disclosed |
| US-20180311265-A1 | Methods and Compositions for Treatment of COPD Diseases | Shanghai KE Pharmaceutical Co., Ltd (CN) | 2018-11-01 | — | — | US | disclosed |
| US-20180280367-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | INTERVET INC. (US) | 2018-10-04 | — | — | US | disclosed |
| EP-1015421-A1 | NEW PHENYLAMIDINE DERIVATIVES, A PROCESS FOR PREPARING THE SAME AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim Pharma KG (DE) | 2000-07-05 | — | — | EP | disclosed |
| WO-2000017176-A2 | BENZOYLGUANIDINE DERIVATIVES WITH ADVANTAGEOUS PROPERTIES, METHOD FOR PRODUCING THEM AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-03-30 | — | — | WO | disclosed |
| EP-0937041-A1 | PURE ENANTIOMER BASIC ARYL-CYCLOALKYL-HYDROXYCARBOXYLIC ACID ESTERS, PROCESS FOR PREPARING THE SAME AND THEIR USE IN MEDICAMENTS | Noe, Christian R. (DE) | 1999-08-25 | — | — | EP | disclosed |
| EP-0882031-A1 | NOVEL BENZOYL GUANIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE PREPARATION OF MEDICINES | Boehringer Ingelheim Pharma KG (DE) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998021183-A1 | PURE ENANTIOMER BASIC ARYL-CYCLOALKYL-HYDROXYCARBOXYLIC ACID ESTERS, PROCESS FOR PREPARING THE SAME AND THEIR USE IN MEDICAMENTS | NOE CHRISTIAN R (AT) | 1998-05-22 | — | — | WO | disclosed |
| WO-1997026253-A1 | NOVEL BENZOYL GUANIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE PREPARATION OF MEDICINES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1997-07-24 | — | — | WO | disclosed |
| WO-1997021670-A1 | NEW PHENYLAMIDINE DERIVATIVES, A PROCESS FOR PREPARING THE SAME AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM KG (DE) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308628-B2 | Heterocyclic compounds and methods for their use | AGTR2, AGTR1, BDKRB2 | TRPA1 155/4885 |
| US-20180280367-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | MPO, DHODH, DHX35 | TRPA1 595/4885 |
| US-20170369473-A1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | AGTR2, AGTR1, AVPR2 | TRPA1 96/4885 |
| US-20040142979-A1 | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | MMP3, MMP13, MMP10 | TRPA1 4404/4885 |
| US-10065943-B2 | Pyrrolidine derivatives as angiotensin II type 2 antagonists | AGTR2, AGTR1, ACE2 | TRPA1 47/4885 |
| US-20180311265-A1 | Methods and Compositions for Treatment of COPD Diseases | MPO, MMP8, COX6C | TRPA1 4762/4885 |
| US-10786521-B2 | Methods and compositions for treatment of COPD diseases | MPO, MMP8, COX6C | TRPA1 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.